Get the Stockscreener App
50.69
0.62%
0.31
Ptc Therapeutics Inc stock is traded at $50.69, with a volume of 414.36K.
It is up +0.62% in the last 24 hours and up +12.02% over the past month.
See More
Previous Close:
$50.38
Open:
$50.73
24h Volume:
414.36K
Relative Volume:
0.59
Market Cap:
$3.33B
Revenue:
$900.66M
Net Income/Loss:
$-453.20M
P/E Ratio:
-8.5337
EPS:
-5.94
Net Cash Flow:
$-274.19M
1W Performance:
-2.18%
1M Performance:
+12.02%
6M Performance:
+49.40%
1Y Performance:
+95.41%
1-Day Range:
$50.03
$51.17
1-Week Range:
$49.39
$52.95
52-Week Range:
$24.00
$54.16
Ptc Therapeutics Inc Stock (PTCT) Company Profile
Name
Ptc Therapeutics Inc
Sector
Industry
Phone
(908) 222-7000
Address
500 WARREN CORPORATE CENTER DRIVE, WARREN, NJ
Compare PTCT with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
PTCT
Ptc Therapeutics Inc
|
50.69 | 3.33B | 900.66M | -453.20M | -274.19M | -5.94 |
|
VRTX
Vertex Pharmaceuticals Inc
|
484.24 | 124.35B | 11.02B | -535.60M | -978.00M | -2.20 |
|
REGN
Regeneron Pharmaceuticals Inc
|
700.33 | 76.56B | 14.20B | 4.41B | 3.54B | 38.28 |
|
ARGX
Argen X Se Adr
|
644.48 | 39.16B | 1.86B | -40.29M | -1.28B | -0.85 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
250.59 | 32.44B | 2.25B | -278.16M | -42.59M | -2.17 |
|
BNTX
Biontech Se Adr
|
120.01 | 28.77B | 3.30B | -501.07M | 1.03B | -2.1146 |
Ptc Therapeutics Inc Stock (PTCT) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Dec-13-24 | Upgrade | Morgan Stanley | Equal-Weight → Overweight |
| Dec-03-24 | Upgrade | RBC Capital Mkts | Sector Perform → Outperform |
| Oct-10-24 | Resumed | Raymond James | Mkt Perform |
| Sep-04-24 | Initiated | Robert W. Baird | Outperform |
| Aug-26-24 | Resumed | UBS | Buy |
| May-20-24 | Upgrade | Raymond James | Underperform → Mkt Perform |
| Dec-19-23 | Downgrade | Morgan Stanley | Equal-Weight → Underweight |
| Dec-08-23 | Initiated | Wells Fargo | Overweight |
| Oct-30-23 | Upgrade | Oppenheimer | Perform → Outperform |
| Oct-27-23 | Downgrade | Citigroup | Neutral → Sell |
| Oct-06-23 | Downgrade | Truist | Buy → Hold |
| Sep-18-23 | Downgrade | Citigroup | Buy → Neutral |
| Sep-15-23 | Downgrade | Raymond James | Outperform → Underperform |
| Mar-17-23 | Initiated | SVB Securities | Market Perform |
| Dec-14-22 | Initiated | Goldman | Sell |
| Sep-12-22 | Initiated | Jefferies | Buy |
| Sep-09-22 | Initiated | Morgan Stanley | Equal-Weight |
| Sep-01-22 | Initiated | Citigroup | Buy |
| Apr-04-22 | Resumed | Cantor Fitzgerald | Overweight |
| Oct-18-21 | Downgrade | BofA Securities | Neutral → Underperform |
| Apr-26-21 | Resumed | Credit Suisse | Neutral |
| Mar-29-21 | Upgrade | RBC Capital Mkts | Underperform → Sector Perform |
| Feb-12-21 | Downgrade | BofA Securities | Buy → Neutral |
| Jan-05-21 | Upgrade | Citigroup | Neutral → Buy |
| Nov-30-20 | Downgrade | RBC Capital Mkts | Sector Perform → Underperform |
| Oct-30-20 | Downgrade | Citigroup | Buy → Neutral |
| Oct-28-20 | Initiated | UBS | Neutral |
| Oct-07-20 | Upgrade | JP Morgan | Neutral → Overweight |
| Aug-25-20 | Initiated | Raymond James | Outperform |
| Apr-09-20 | Upgrade | Citigroup | Neutral → Buy |
| Feb-20-20 | Downgrade | Citigroup | Buy → Neutral |
| Feb-20-20 | Downgrade | RBC Capital Mkts | Outperform → Sector Perform |
| Nov-12-19 | Initiated | SunTrust | Buy |
| May-13-19 | Upgrade | BofA/Merrill | Neutral → Buy |
| Apr-11-19 | Initiated | Bernstein | Outperform |
| Oct-03-18 | Upgrade | BofA/Merrill | Underperform → Neutral |
| Oct-01-18 | Initiated | Cantor Fitzgerald | Overweight |
| Jul-19-18 | Initiated | Credit Suisse | Outperform |
| Jun-18-18 | Upgrade | RBC Capital Mkts | Sector Perform → Outperform |
| Apr-04-18 | Downgrade | Barclays | Equal Weight → Underweight |
| Jan-29-18 | Resumed | RBC Capital Mkts | Sector Perform |
| Nov-16-17 | Upgrade | JP Morgan | Underweight → Neutral |
| Oct-26-17 | Downgrade | BofA/Merrill | Neutral → Underperform |
| Oct-09-17 | Downgrade | JP Morgan | Neutral → Underweight |
View All
Ptc Therapeutics Inc Stock (PTCT) Latest News
PTC Therapeutics CEO Eric Pauwels sells $147,576 in stock By Investing.com - Investing.com Australia
PTC Therapeutics' chief accounting officer sells $88,043 in stock By Investing.com - Investing.com Australia
Hussman Strategic Advisors Inc. Buys Shares of 21,000 PTC Therapeutics, Inc. (NASDAQ:PTCT) - MarketBeat
PTC Therapeutics CFO sells $117,006 in stock By Investing.com - Investing.com Australia
PTC Therapeutics CEO Matthew Klein sells $390,457 in stock By Investing.com - Investing.com Nigeria
PTC Therapeutics CFO sells $117,006 in stock - Investing.com India
PTC Therapeutics EVP Scott sells $88,045 in stock - Investing.com India
PTC Therapeutics' chief accounting officer sells $88,043 in stock - Investing.com
PTC Therapeutics Executives Sell Shares to Cover Tax Obligations - TradingView
PTC Therapeutics EVP Scott sells $88,045 in stock By Investing.com - Investing.com UK
PTC Therapeutics (NASDAQ:PTCT) Downgraded by StockNews.com to "Hold" - MarketBeat
PTC Therapeutics (PTCT) Projected to Post Quarterly Earnings on Thursday - MarketBeat
PTC Therapeutics (PTCT) Expected to Beat Earnings Estimates: Can the Stock Move Higher? - Nasdaq
PTC Therapeutics Announces FDA Acceptance and Priority Review for Vatiquinone NDA for the Treatment of Children and Adults with Friedreich's Ataxia - Marketscreener.com
How PTC Therapeutics Will Shape Its Story at Two Major Healthcare Conferences - StockTitan
Vontobel Holding Ltd. Takes Position in PTC Therapeutics, Inc. (NASDAQ:PTCT) - MarketBeat
PTC Therapeutics, Inc. (NASDAQ:PTCT) Given Consensus Recommendation of "Hold" by Brokerages - MarketBeat
FDA accepts new drug application for vatiquinone to treat Friedreich's ataxia - Contemporary Pediatrics
PTC Therapeutics (NASDAQ:PTCT) Price Target Raised to $63.00 - MarketBeat
PTC Therapeutics Says FDA Grants Priority Review to Vatiquinone NDA for Treating Friedreich's Ataxia; Shares Up Pre-Bell - Marketscreener.com
FDA grants priority review for potential Friedreich's ataxia drug - Investing.com India
Ptc Therapeutics Announces FDA Acceptance And Priority Review For Vatiquinone NDA - TradingView
Could This Rare Disease Drug Be PTC's Next Breakthrough? FDA Priority Review Reveals Major Potential - StockTitan
RBC Capital Adjusts PTC Therapeutics Price Target to $63 From $60, Maintains Outperform Rating - Marketscreener.com
PTC Therapeutics, Inc. (NASDAQ:PTCT) Shares Sold by Apollon Wealth Management LLC - MarketBeat
PTC Therapeutics (NASDAQ:PTCT) Price Target Raised to $45.00 - MarketBeat
PTC Therapeutics to Host Conference Call to Discuss Fourth Quarter and Full Year 2024 Financial Results - Quantisnow
PTC Therapeutics' (NASDAQ:PTCT) investors will be pleased with their solid 101% return over the last year - Simply Wall St
PTC Therapeutics (NASDAQ:PTCT) Upgraded at StockNews.com - MarketBeat
(PTCT) Trading Report - Stock Traders Daily
PTC Therapeutics rises 9% after Cantor raises price target to Street high - MSN
Rett Syndrome Market Growth Projections 2024-2034: - openPR
PTC Therapeutics (NASDAQ:PTCT) Trading 6.1% Higher Following Analyst Upgrade - MarketBeat
PTC Therapeutics (NASDAQ:PTCT) Price Target Raised to $113.00 at Cantor Fitzgerald - MarketBeat
PTC Therapeutics' SWOT analysis: stock poised for growth amid regulatory challenges - MSN
Cantor Fitzgerald Issues Negative Estimate for PTCT Earnings - MarketBeat
Duchenne Muscular Dystrophy Market Report 2034: Epidemiology - openPR
PTC Therapeutics price target raised to $113 from $76 at Cantor Fitzgerald - Yahoo Finance
PTC Therapeutics (PTCT) Moves 9.0% Higher: Will This Strength Last? - Yahoo Finance
Cantor Fitzgerald lifts PTC Therapeutics stock target to $113 By Investing.com - Investing.com Canada
Why PTC Therapeutics (PTCT) Stock Is Rallying Today - Insider Monkey
Cantor Fitzgerald lifts PTC Therapeutics stock target to $113 - MSN
Ptc Therapeutics Inc Stock (PTCT) Financials Data
Revenue
Net Income
Cash Flow
EPS
Ptc Therapeutics Inc Stock (PTCT) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| Utter Christine Marie | SVP, CHIEF ACCOUNTING OFFICER |
Feb 20 '25 |
Sale |
50.12 |
878 |
44,009 |
62,564 |
| Gravier Pierre | CHIEF FINANCIAL OFFICER |
Feb 19 '25 |
Sale |
50.10 |
1,168 |
58,512 |
75,603 |
| Gravier Pierre | CHIEF FINANCIAL OFFICER |
Feb 20 '25 |
Sale |
50.12 |
1,167 |
58,495 |
74,436 |
| Pauwels Eric | CHIEF EXECUTIVE OFFICER |
Feb 20 '25 |
Sale |
50.12 |
1,567 |
78,544 |
83,860 |
| Pauwels Eric | CHIEF EXECUTIVE OFFICER |
Feb 19 '25 |
Sale |
50.10 |
1,378 |
69,032 |
85,427 |
| Klein Matthew B. | CHIEF EXECUTIVE OFFICER |
Feb 20 '25 |
Sale |
50.12 |
3,895 |
195,233 |
276,038 |
| Klein Matthew B. | CHIEF EXECUTIVE OFFICER |
Feb 19 '25 |
Sale |
50.10 |
3,897 |
195,224 |
279,933 |
| Golden Lee Scott | EVP & CHIEF MEDICAL OFFICER |
Feb 20 '25 |
Sale |
50.12 |
962 |
48,219 |
76,894 |
| Golden Lee Scott | EVP & CHIEF MEDICAL OFFICER |
Feb 19 '25 |
Sale |
50.10 |
795 |
39,826 |
77,856 |
| Boulding Mark Elliott | EXEC. VP AND CLO |
Feb 20 '25 |
Sale |
50.12 |
1,614 |
80,900 |
103,901 |
0.27%
3.05%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):